MedTrace Logo

Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

NCT06425120 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2025-09-08

No results posted yet for this study

Summary

This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.

Conditions

Interventions

DRUG

Xuesaitong Soft Capsule

Each participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.

DRUG

Placebo

Each participant in the placebo group will take matching placebo.

Sponsors & Collaborators

  • China National Center for Cardiovascular Diseases

    lead OTHER_GOV

Principal Investigators

  • Jing Li, MD, PhD · National Center for Cardiovascular Diseases

  • Jiamin Liu, MD · National Center for Cardiovascular Diseases

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06425120 on ClinicalTrials.gov